Literature DB >> 3086274

An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.

S S Pedersen, C Koch, N Høiby, K Rosendal.   

Abstract

Early in 1983 an epidemic of a Pseudomonas aeruginosa resistant to aminoglycosides, carbenicillin, ureidopenicillins, ceftazidime, cefsulodin and imipenem occurred in a cystic fibrosis centre. Most of the epidemic could be attributed to a specific nosocomial strain by means of O-grouping and phage-typing. This strain was present in the centre at a low frequency in 1973 and developed resistance during courses of chemotherapy. The epidemic was stopped by isolating patients with the resistant strains. Restrictive and selective use of antibiotics have not been sufficient to eradicate the resistant strains, which persist in 42% of the patients. The extensive use of the third generation cephalosporins in the clinic is probably responsible for inducing and selecting for the resistant strains. Clustering of patients in the centre has facilitated the spread. First-line use of older beta-lactam antibiotics, close bacteriological monitoring and prompt isolation of patients with resistant strains are recommended.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086274     DOI: 10.1093/jac/17.4.505

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  50 in total

1.  Evaluation of random amplified polymorphic DNA typing of Pseudomonas aeruginosa.

Authors:  M Campbell; E Mahenthiralingam; D P Speert
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

Review 2.  Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex.

Authors:  J R Govan
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

Review 3.  Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp.

Authors:  Andrew M Jones; A Kevin Webb
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 4.  Resistance to third generation cephalosporins: the current situation.

Authors:  J C Pechère
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

5.  Heterogeneity, persistence, and distribution of Pseudomonas aeruginosa genotypes in cystic fibrosis patients.

Authors:  M Fegan; P Francis; A C Hayward; J A Fuerst
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

Review 6.  Carbapenem-Resistant Non-Glucose-Fermenting Gram-Negative Bacilli: the Missing Piece to the Puzzle.

Authors:  Thomas J Gniadek; Karen C Carroll; Patricia J Simner
Journal:  J Clin Microbiol       Date:  2016-02-24       Impact factor: 5.948

7.  Conversion of Pseudomonas aeruginosa to the phenotype characteristic of strains from patients with cystic fibrosis.

Authors:  D P Speert; S W Farmer; M E Campbell; J M Musser; R K Selander; S Kuo
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

8.  Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Authors:  Michael D Parkins; Bryan A Glezerson; Christopher D Sibley; Kristen A Sibley; Jessica Duong; Swathi Purighalla; Christopher H Mody; Matthew L Workentine; Douglas G Storey; Michael G Surette; Harvey R Rabin
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

9.  Comparison of three typing methods for Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  V Waters; J E A Zlosnik; Y C W Yau; D P Speert; S D Aaron; D S Guttman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-29       Impact factor: 3.267

10.  Genome macrorestriction analysis of diversity and variability of Pseudomonas aeruginosa strains infecting cystic fibrosis patients.

Authors:  M J Struelens; V Schwam; A Deplano; D Baran
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.